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In the BIOMArCS-2 Glucose (Randomized Trial to Evaluate the Clinical Value of Intensive Glucose Monitoring and Regulation in Myocardial Infarction) trial, intensive glucose control (IGC) did not reduce myocardial infarction (MI) size in ST-segment–elevation 
MI or non–ST-segment–elevation MI patients presenting with hyperglycemia. In fact, IGC 
was associated with excess in-hospital death or MI (8 versus 1 event).1 Because these 
findings were unexpected, we executed a longer-term extension of the original trial co-
hort.
In BIOMArCS-2 Glucose, 280 MI patients with admission blood glucose 140 to 
288 mg/dL were randomly assigned to either IGC with intravenous insulin for 48 
hours aiming for plasma levels of 85 to 110 mg/dL versus conventional manage-
ment (control).1 The protocol was approved by the local Medical Ethics committee, 
and all patients provided written informed consent.
In January 2016, median follow-up was 5.1 years (interquartile range, 4.0–6.2). We 
obtained data on vital status from municipal registries and on MI by reviewing medical 
records. MI was defined as typical chest pain accompanied by a rise of troponins. Follow-
up on all-cause death and MI was 99.3% and 97.5% of patients, respectively. Patients 
with incomplete follow-up data were censored after their last hospital visit.
The Figure demonstrates the cumulative incidence of death or MI for the study 
groups. For this composite end point, there was an early higher hazard for the IGC 
patients after the intervention (30-day Kaplan-Meier estimate: 8.6% (95% confidence 
interval [CI], 5.0–15.0) versus 1.4% [95% CI, 0–6.0]; Plog-rank=0.006). On the basis of 
a Cox model, IGC patients had a 6.2-fold (95% CI, 1.4–27.6) increased risk of death 
or MI during the first 30 days. There was a higher number of deaths or MIs in the IGC 
group after longer-term follow-up, although this difference was no longer statistically 
significant (Kaplan-Meier estimates of 27.0 [95% CI, 21.0–37.0] versus 22.0% [95% 
CI, 15.0–32.0]; Plog-rank=0.106).
The Kaplan-Meier curves for incidence of death showed a pattern similar to that 
of the composite end point (Figure B). Although the number of deaths was small, 
IGC patients had a significantly higher 30-day mortality than controls (4/140 versus 
0/140 patients, Plogrank=0.044). This difference persisted through long-term follow-
up (23 versus 12 deaths, Plogrank=0.048).
It is noteworthy that 2 of the 19 IGC patients who died after 30 days had a recur-
rent MI just after the index MI. We found no relationship between severe hypoglyce-
mia (blood glucose <50 mg/dL) during the IGC intervention and cardiovascular end 
points. However, given the stringent application of the study protocol, glucose was 
tightly regulated with low numbers of severe hypoglycemia (n=13, with 3 MIs and 
2 deaths).
Our trial results suggest that lowering blood glucose in hyperglycemic MI pa-
tients by a 48-hour insulin-based IGC strategy leads to excess mortality and MI 
during the first 30 days that persisted through longer-term follow-up. The Kaplan-
Meier curves display a parallel course, and the early difference in mortality per-
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sists. Hence, chance is an unlikely explanation of our 
findings of worse outcomes with IGC. We hypothesize 
that hyperglycemia during an acute MI is part of the 
physiological (protective?) metabolic stress reaction 
of the body. Strict lowering of blood glucose levels 
may result in a patient- and event-specific relative hy-
poglycemia, leading to an increased risk of cardiovas-
cular events. Although an association between severe 
Figure. Kaplan-Meier curves for end points. 
A, All-cause mortality and MI. Inset, Curve for the first 30 days for the composite end point. Middle, Curve for the total cohort. 
B, All-cause mortality. Inset, Curve for the first 30 days. Middle, Curve for the total cohort. The green line is the IGC group; and 
the blue line is the intervention group. IGC indicates intensive glucose control; and MI, myocardial infarction.
 by guest on O
ctober 10, 2016
http://circ.ahajournals.org/
D
ow
nloaded from
 
van den Berg et al
September 27, 2016 Circulation. 2016;134:984–986. DOI: 10.1161/CIRCULATIONAHA.116.023480986
hypoglycemia and the end points would also be in line 
with this hypothesis, we could not demonstrate such 
an association. Low numbers of severe hypoglycemic 
events may have precluded this.
Our results are comparable to those from the NICE-
SUGAR (Normoglycaemia in Intensive Care Evaluation 
and Survival Using Glucose Algorithm Regulation) trial, 
which compared a (median) 4-day intervention of intra-
venous insulin targeting plasma glucose 81 to 108 mg/
dL versus conventional glucose treatment with a target 
of a maximum of 180 mg/dL in patients in the intensive 
care unit, and reported increased mortality at 90 days in 
the IGC group.2 Obviously, NICE-SUGAR and BIOMArCS-2 
Glucose had different target populations. However, in 
both trials, the IGC strategy resulted in a rapid reduc-
tion of plasma glucose to nearly normal levels. Other 
MI trials that did not find ICG-related adverse outcomes 
largely failed to realize a significant difference in 24-hour 
plasma glucose between active treatment and control.3,4 
Whereas in the landmark DIGAMI trial (Diabetes Mellitus 
Insulin-Glucose Infusion in Acute Myocardial Infarction),5 
24-hour plasma glucose was significantly reduced by 
IGC without adverse effects, the (mean) value remained 
as high as 172.8 mg/dL, in comparison with 106.2 in 
our trial. It would be interesting to investigate how a less 
stringent glucose intervention would compare with a 
conventional watch-and-see treatment in hyperglycemic 
MI patients.
A limitation of our study is the observational, non-
planned nature of our follow-up data without scheduled 
follow-up visits, and the ensuing lack of repeated assess-
ment of patient characteristics.
In conclusion, IGC with intravenous insulin resulted in 
an excess of the composite of mortality and reinfarc-
tion at 30 days after the index event. Although no longer 
statistically significant, the absolute difference in events 
that emerged in this first period persisted during long-
term follow-up, suggesting that the increased 30-day 
risk was not because of chance. The risk of mortality 
remained significantly higher during long-term follow-up. 
Our current findings confirm our previous recommenda-
tions that IGC in hyperglycemic MI patients is not associ-
ated with improved outcomes.1
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